Posted by Michael Wonder on 12 Feb 2024
GSK receives US FDA fast track designation for bepirovirsen in chronic hepatitis B
12 February 2024 - Designation underscores the unmet need for medicines that can achieve functional cure in patients with chronic hepatitis B.
GSK announced today that the US FDA has granted fast track designation for bepirovirsen, an investigational antisense oligonucleotide for the treatment of chronic hepatitis B.
